A major chemical services supplier has invested more than Pounds 1 million in a spin-off company from Strathclyde University's department of pharmaceutical sciences, which formulates and manufactures new drugs for use in clinical trials.
Oxford Asymmetry International (OAI) has invested Pounds 1.1 million in return for a 58 per cent equity stake in the Glasgow based company, ProPharma, with an option to purchase the remaining 42 per cent over three years.
Register to continue
Get a month's unlimited access to THE content online. Just register and complete your career summary.
Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:
- Sign up for the editor's highlights
- Receive World University Rankings news first
- Get job alerts, shortlist jobs and save job searches
- Participate in reader discussions and post comments
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber?Sign in now